Welcome to our dedicated page for PomDoctor news (Ticker: POM), a resource for investors and traders seeking the latest updates and insights on PomDoctor stock.
Pepco (POM), a key Exelon Corporation subsidiary, delivers essential electric services to Washington, DC and surrounding regions while driving grid modernization efforts. This dedicated news hub provides investors and stakeholders with official updates on the company's operational milestones and strategic direction.
Access timely reports on infrastructure upgrades, financial performance, and sustainability initiatives. Our curated collection features press releases about grid reliability projects, workforce development achievements like those of Danielle Powell and Ashanti Hunt, and partnerships advancing renewable energy integration.
Discover updates on Pepco's regulatory compliance progress, community engagement programs, and technological innovations in power distribution. The resource serves as your primary source for understanding the company's role in shaping the Mid-Atlantic energy landscape.
Bookmark this page for direct access to verified information about POM's operational strategies, financial health, and commitment to sustainable energy solutions. Check regularly for new developments impacting one of Exelon's most strategically important regional utilities.
POMDOCTOR (Nasdaq: POM) announced the underwriter fully exercised its over-allotment option to purchase 750,000 ADSs at $4.00 per ADS, with the over-allotment closing on October 10, 2025. Gross proceeds to the company from the Offering, including the prior closing and this exercise, totaled $23,000,016 before underwriting discounts and expenses. The ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker POM. The Offering was conducted on a firm commitment basis, with Joseph Stone Capital acting as underwriter. The SEC declared the company’s Form F-1 effective on September 30, 2025.
POMDOCTOR (Nasdaq: POM) closed its initial public offering on Oct 9, 2025, selling 5,000,004 ADSs at $4.00 per ADS (six ADSs equal one Class A ordinary share). The ADSs began trading on the Nasdaq Global Market on Oct 8, 2025 under ticker POM. The company received aggregate gross proceeds of approximately $20.0 million before underwriting discounts and expenses. The underwriter, Joseph Stone Capital, was granted a 45-day option to buy up to an additional 750,000 ADSs at the public offering price less underwriting discounts. The offering was conducted on a firm commitment basis.
POMDOCTOR (NASDAQ:POM) priced its initial public offering of 5,000,004 ADSs at $4.00 per ADS, implying aggregate gross proceeds of approximately $20.0 million before underwriting discounts and expenses. Six ADSs represent one Class A ordinary share. The ADSs were approved to list on the Nasdaq Global Market and are expected to commence trading on October 8, 2025 under the ticker POM. The offering is expected to close on or about October 9, 2025 and includes a 45-day underwriter option for 750,000 ADSs.
FAQ
What is the current stock price of PomDoctor (POM)?
What is the market cap of PomDoctor (POM)?
